Thrombolysis Using Tenecteplase (Metalyse®) in Cardiac Arrest - The TROICA Trial

NCT ID: NCT00157261

Last Updated: 2013-10-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

1050 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-01-31

Study Completion Date

2006-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The general aim of this study is to compare the efficacy and safety of tenecteplase to standard treatment during cardiopulmonary resuscitation in patients suffering from out-of-hospital cardiac arrest.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The trial is a prospective, international, multi-centre, randomised (1:1), double-blind, parallel group comparison conducted for investigating the efficacy and safety of tenecteplase and placebo in patients with cardiac arrest of presumed cardiac origin.

Approximately 1300 patients (two groups of 650 patients; tenecteplase or matching placebo) suffering from witnessed (by eye or ear) out-of-hospital cardiac arrest of presumed cardiac origin, who are treated with ALS-CPR will be randomised at approximately 40 study centres. Randomisation is done immediately after insertion of an IV line is established. Study drug application, as a single IV bolus over 5-10 seconds, should be done immediately after the first vasopressor application during the ALS-CPR procedure.

PCI facilities will be required at all participating sites, i.e. hospitals receiving patients.

Study Hypothesis:

The primary aim of the trial is to demonstrate superiority in the intent-to-treat analysis of tenecteplase over placebo with regard to primary endpoint as the incidence of 30-day survival (30daysurv).

Comparison(s):

Group A (experimental; fibrinolytic treatment) Tenecteplase, as a single IV bolus over 5-10 seconds, immediately after first vasopressor dosage during standardised ALS-CPR procedures according to the International CPR Guidelines.

Group B (reference) Placebo, as a single IV bolus over 5-10 seconds, immediately after first vasopressor dosage during standardised ALS-CPR procedures according to the International CPR Guidelines.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Arrest

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

tenecteplase

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age at least 18 years (known or estimated; no upper limit)
* Out-of-hospital cardiac arrest of presumed cardiac origin (including recurrent cardiac arrest(s) after initial ROSC)
* Witnessed (by eye and/or ear) cardiac arrest
* BLS-CPR started within 10 min of onset (known or estimated time) and may be performed for up to 10 min, followed by ALS-CPR - or ALS-CPR started within 10 min of onset (known or estimated time)

Subjects who meet any of the following criteria will be excluded from randomisation into the study:

* In-hospital cardiac arrest
* Cardiac arrest of presumed non-cardiac origin (e.g., drug overdose, carbon monoxide poisoning, drowning, hypothermia, exsanguination, electrocution, asphyxia, hypoxia, trauma, cerebrovascular accident)
* Obvious significant internal bleeding
* Known neurological impairment
* Known coagulation disorder
* Known pregnancy
* Known current participation in any other clinical study
* Known hypersensitivity to study medication
* Institutionalised subjects (e.g., prisoner)
* Any other condition that the investigator feels would place the patient at increased risk if the investigational therapy is initiated
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Boehringer Ingelheim Study Coordinator

Role: STUDY_CHAIR

B.I. Pharma GmbH & Co. KG

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Univ.-Klinik f. Anaesthesie Graz

Graz, , Austria

Site Status

Univ.-Klinik f. Anaesthesie u. Intensivmedizin

Innsbruck, , Austria

Site Status

LKH Salzburg, St. Johanns-Spital

Salzburg, , Austria

Site Status

Univ.-Klinik f. Notfallmedizin

Vienna, , Austria

Site Status

Algemeen Ziekenhuis Antwerpen / Campus Stuivenberg

Antwerp, , Belgium

Site Status

AZ Sint-Jan AV

Bruges, , Belgium

Site Status

CHU Saint-Pierre

Brussels, , Belgium

Site Status

AZ VUB

Brussels, , Belgium

Site Status

Cliniques Universitaires Saint-Luc

Brussels, , Belgium

Site Status

AZ Groeningen

Kortrijk, , Belgium

Site Status

CHU de Tivoli

La Louvière, , Belgium

Site Status

Universitaire Ziekenhuizen Leuven

Leuven, , Belgium

Site Status

CHR de la Citadelle

Liège, , Belgium

Site Status

CHR de Namur

Namur, , Belgium

Site Status

Hôpital Jean Minjoz

Besançon, , France

Site Status

Hôpital Avicenne

Bobigny, , France

Site Status

Hôpital Henri Mondor

Créteil, , France

Site Status

Hôpital André Mignot

Le Chesnay, , France

Site Status

Hôpital Régional et Universitaire

Lille, , France

Site Status

Hôpital Marc Jacquet

Melun, , France

Site Status

Hôpital Lapeyronie

Montpellier, , France

Site Status

Hôpital Necker

Paris, , France

Site Status

Hôpital Charles Nicolle

Rouen, , France

Site Status

Hôpital Purpan

Toulouse, , France

Site Status

Hôpital Pierre Bazin

Voiron, , France

Site Status

Universitätsklinikum Benjamin Franklin

Berlin, , Germany

Site Status

Humboldt-Klinikum

Berlin, , Germany

Site Status

DRK Kliniken Westend

Berlin, , Germany

Site Status

Städtische Kliniken Bielefeld gem. GmbH

Bielefeld, , Germany

Site Status

Klinikum der Ruhr-Universität Bochum

Bochum, , Germany

Site Status

Knappschaftskrankenhaus Dortmund

Dortmund, , Germany

Site Status

Chirurgische Universität Freiburg

Freiburg/Breisgau, , Germany

Site Status

Georg-August Universität Göttingen

Göttingen, , Germany

Site Status

Martin-Luther-Universität Halle

Halle, , Germany

Site Status

Universität Heidelberg

Heidelberg, , Germany

Site Status

Friedrich-Schiller Universität Jena

Jena, , Germany

Site Status

Universitätsklinikum Schleswig-Holstein

Kiel, , Germany

Site Status

Berufsfeuerwehr Kiel

Kiel, , Germany

Site Status

Universitätsklinikum Mannheim

Mannheim, , Germany

Site Status

Klinikum rechts der Isar

München, , Germany

Site Status

Klinikum Saarbrücken gGmbH

Saarbrücken, , Germany

Site Status

Universitätsklinikum Ulm

Ulm, , Germany

Site Status

A. O. Ospedali Riuniti di Bergamo

Bergamo, , Italy

Site Status

Ospedale S. Anna

Como, , Italy

Site Status

A. O. Universitaria S. Martino

Genova, , Italy

Site Status

A. O. San Gerardo di Monza

Monza, , Italy

Site Status

Policlinico S. Matteo

Pavia, , Italy

Site Status

Osp. di Circolo Fondazione Macchi

Varese, , Italy

Site Status

ICU, Haukeland Universitetssykehus

Bergen, , Norway

Site Status

ICU, Sykehuset Østfold Fredrikstad

Fredrikstad, , Norway

Site Status

Akuttklinikken / NLA, Sentralsjukehuset i Rogaland

Stavanger, , Norway

Site Status

Pre Hospital Klinikk, Sykehuset i Vestfold Tønsberg

Tønsberg, , Norway

Site Status

Hospital de Torrecárdenas / ICU

Almería, , Spain

Site Status

Hospital Clínico Provincial de BCN / Cardiology Service

Barcelona, , Spain

Site Status

Hospital Universitario Reina Sofía / ICU

Córdoba, , Spain

Site Status

Vírgen de las Nieves. Critical Care-Emergency Room

Granada, , Spain

Site Status

Hospital de Jerez de la Frontera / ICU

Jerez de la Frontera, , Spain

Site Status

Hospital Clínico San Carlos / Hemodynamics

Madrid, , Spain

Site Status

Hospital Clínico Universitario Vírgen de la Victoria / ICU

Málaga, , Spain

Site Status

Boehringer Ingelheim Investigational Site

Seville, , Spain

Site Status

Complejo Hospitalario Universitario de Vigo / Cardiology

Vigo, , Spain

Site Status

Hospital Clinico Univ. Lozano Blesa

Zaragoza, , Spain

Site Status

Anestesikliniken

Gävle, , Sweden

Site Status

Hjärt/Kärlforskn.enheten, Sahlgrenska Univ.sjh. Göteborg

Gothenburg, , Sweden

Site Status

Universitetssjukhuset

Örebro, , Sweden

Site Status

Södersjukhuset

Stockholm, , Sweden

Site Status

Centre interdisciplinaire des urgences (CIU), CHUV BH 06-429

Lausanne, , Switzerland

Site Status

Boehringer Ingelheim Investigational Site

Lugano, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Austria Belgium France Germany Italy Norway Spain Sweden Switzerland

References

Explore related publications, articles, or registry entries linked to this study.

Bottiger BW, Arntz HR, Chamberlain DA, Bluhmki E, Belmans A, Danays T, Carli PA, Adgey JA, Bode C, Wenzel V; TROICA Trial Investigators; European Resuscitation Council Study Group. Thrombolysis during resuscitation for out-of-hospital cardiac arrest. N Engl J Med. 2008 Dec 18;359(25):2651-62. doi: 10.1056/NEJMoa070570.

Reference Type DERIVED
PMID: 19092151 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1123.18

Identifier Type: -

Identifier Source: org_study_id